User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.

Primary tabs

Perros, Petros Žarković, Miloš Azzolini, Claudio Ayvaz, Göksun Baldeschi, Lelio [UCL] Boschi, Antonella [UCL] Daumerie, Chantal [UCL] Törüner, Fosun Baloş

(eng) BACKGROUND/AIMS: The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time. METHODS: Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000. RESULTS: The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, including smoking rates (40.0% vs 40.2%). Mild (60.5% vs 41.2%, p<0.01) and inactive GO (63.2% vs 39.9%, p<0.01) were more prevalent in 2012. The times from diagnosis of thyroid disease to being seen in EUGOGO centres (6 vs 16 months) and from first symptoms of GO (9 vs 16 months) or from diagnosis of GO (6 vs 12 months) to first consultation in EUGOGO centres were shorter in 2012 (p<0.01). The initial management plans for GO were no different except surgical treatments for patients with mild inactive disease were more frequently offered in the 2012 cohort than in 2000 (27.3% vs 17%, p<0.05), and selenium supplements were offered only in the 2012 cohort (21.2% vs 0%, p<0.01). CONCLUSIONS: These findings suggest that the clinical manifestations of patients with GO may be changing over time in Europe.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2015
Language Anglais
Journal information "British Journal of Ophthalmology" - Vol. 99, no.11, p. 1531-1535 (2015)
Peer reviewed yes
Publisher B M J Group (London)
issn 0007-1161
e-issn 1468-2079
Publication status Publié
Affiliations UCL - SSS/IONS/NEUR - Clinical Neuroscience
UCL - (SLuc) Service d'ophtalmologie
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - (SLuc) Service d'endocrinologie et de nutrition
UCL - SSS/IONS - Institute of NeuroScience
Keywords Epidemiology ; Orbit
Links
  1. Terwee C. B., Dekker F. W., Mourits M.P., Gerding M. N., Baldeschi L., Kalmann R., Prummel M. F., Wiersinga W. M., Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments, 10.1046/j.1365-2265.2001.01241.x
  2. Hegedüs Laszlo, Brix T. H., Vestergaard P., Relationship between cigarette smoking and Graves’ ophthalmopathy, 10.1007/bf03345276
  3. Piantanida, J Endocrinol Invest, 36, 444 (2013)
  4. Lazarus John H., Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease, 10.1016/j.beem.2011.10.005
  5. Tanda M. L., Piantanida E., Liparulo L., Veronesi G., Lai A., Sassi L., Pariani N., Gallo D., Azzolini C., Ferrario M., Bartalena L., Prevalence and Natural History of Graves' Orbitopathy in a Large Series of Patients With Newly Diagnosed Graves' Hyperthyroidism Seen at a Single Center, 10.1210/jc.2012-3873
  6. Daumerie Ch., Duprez Th., Boschi A., Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy, 10.1016/j.ejim.2008.01.013
  7. Perros Petros, Wiersinga Wilmar M., The Amsterdam Declaration on Graves' Orbitopathy, 10.1089/thy.2010.1618
  8. Marcocci Claudio, Marinò Michele, Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy, 10.1016/j.beem.2011.11.005
  9. Hegedüs Laszlo, Bonnema Steen J., Smith Terry J., Brix Thomas H., Treating the thyroid in the presence of Graves’ ophthalmopathy, 10.1016/j.beem.2011.09.005
  10. Bartalena, Endocr Rev, 21, 168 (2000)
  11. Bartalena Luigi, Marcocci Claudio, Bogazzi Fausto, Manetti Luca, Tanda Maria Laura, Dell'Unto Enrica, Bruno-Bossio Gabriella, Nardi Marco, Bartolomei Maria Pia, Lepri Antonio, Rossi Giuseppe, Martino Enio, Pinchera Aldo, Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy, 10.1056/nejm199801083380201
  12. Bartalena Luigi, Fatourechi Vahab, Extrathyroidal manifestations of Graves’ disease: a 2014 update, 10.1007/s40618-014-0097-2
  13. da Silva F L M, de Lourdes Veronese Rodrigues M, Akaishi P M S, Cruz A A V, Graves' orbitopathy: frequency of ocular hypertension and glaucoma, 10.1038/eye.2008.155
  14. Haefliger I., von Arx G., Pimentel A.-R., Pathophysiology of Intraocular Pressure Increase and Glaucoma Prevalence in Thyroid Eye Disease: A Mini-Review, 10.1055/s-0029-1245199
  15. Agresti Alan, Categorical Data Analysis, ISBN:0471360937, 10.1002/0471249688
  16. , Wiersinga W M, Perros P, Kahaly G J, Mourits M P, Baldeschi L, Boboridis K, Boschi A, Dickinson A J, Kendall-Taylor P, Krassas G E, Lane C M, Lazarus J H, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel M F, Sartini M S, Stahl M, von Arx G, Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers, 10.1530/eje.1.02230
  17. Bartalena L., Krassas G. E., Wiersinga W., Marcocci C., Salvi M., Daumerie C., Bournaud C., Stahl M., Sassi L., Veronesi G., Azzolini C., Boboridis K. G., Mourits M. P., Soeters M. R., Baldeschi L., Nardi M., Currò N., Boschi A., Bernard M., von Arx G., , Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy, 10.1210/jc.2012-2389
  18. Marcocci Claudio, Kahaly George J., Krassas Gerasimos E., Bartalena Luigi, Prummel Mark, Stahl Matthias, Altea Maria Antonietta, Nardi Marco, Pitz Susanne, Boboridis Kostas, Sivelli Paolo, von Arx George, Mourits Maarten P., Baldeschi Lelio, Bencivelli Walter, Wiersinga Wilmar, Selenium and the Course of Mild Graves' Orbitopathy, 10.1056/nejmoa1012985
  19. Prummel M., Bakker A, Wiersinga W., Baldeschi L, Mourits M., Kendall-Taylor P, Perros P, Neoh C, Dickinson A., Lazarus J., Lane C., Heufelder A., Kahaly G., Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini M., Rocchi R, Nardi M, Krassas G., Halkias A, Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience, 10.1530/eje.0.1480491
  20. Wiersinga Wilmar M., Smoking and thyroid, 10.1111/cen.12222
  21. Eckstein A. K., Johnson K. T. M., Thanos M., Esser J., Ludgate M., Current Insights into the Pathogenesis of Graves’ Orbitopathy, 10.1055/s-0029-1220935
  22. Brix, J Clin Endocrinol Metab, 86, 930 (2001)
  23. Wang Yao, Smith Terry J., Current Concepts in the Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy, 10.1167/iovs.14-14002
  24. Putta-Manohar, Pediatr Endocrinol Rev, 7, 182 (2010)
  25. PERROS PETROS, KENDALL-TAYLOR PAT, Natural History of Thyroid Eye Disease, 10.1089/thy.1998.8.423
Bibliographic reference Perros, Petros ; Žarković, Miloš ; Azzolini, Claudio ; Ayvaz, Göksun ; Baldeschi, Lelio ; et. al. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.. In: British Journal of Ophthalmology, Vol. 99, no.11, p. 1531-1535 (2015)
Permanent URL http://hdl.handle.net/2078.1/166580